← All trials
NCT06630884
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Nov 30, 2028
- Completion date
- Nov 30, 2028
- First posted
- Oct 8, 2024
- Last posted
- Oct 8, 2024
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Northern California Institute of Research and EducationCollaborator
- University of California, San FranciscoOfficial
- National Institute of Mental Health (NIMH)Collaborator
- Department of Veteran AffairsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.